Sermorelin

Sermorelin is the shortest fully active fragment of the 44-amino-acid hypothalamic GHRH, and it acts identically at the GHRH receptor, raising cAMP in somatotrophs and driving both GH synthesis and release. Because it works upstream of the pituitary and the response is still gated by somatostatin and by IGF-1 negative feedback, the GH rise remains within physiological bounds and the axis effectively cannot be overdriven the way it can with exogenous GH. Its clinical drawback is a very short half-life of about ten minutes and rapid DPP-4 cleavage at the N-terminus, which is what the modified analogues were designed to fix. A useful side effect is that a preserved response identifies a pituitary that still works, which is why it was originally approved as a diagnostic agent as well as a therapy.

Targets: GHRH receptor (GHRHR), Pituitary somatotrophs, IGF-1 axis

• · This is what most anti-aging and hormone clinics prescribe. 300 mcg nightly is the most common single starting point.
• · Used when IGF-1 fails to move at 300 mcg. Above 1 mg the dose-response flattens and cost rises faster than benefit.
• · Common in clinics that compound blends; the GHRP does most of the heavy lifting.

Work out your exact syringe units →

• very commonInjection-site redness, swelling or pain— The most frequently reported effect in the original clinical trials.
• commonFlushing— Transient, minutes.
• uncommonHeadache
• uncommonDizziness
• uncommonAltered taste, often metallic— Reported in the label; transient.
• rareWater retention or joint aching— Much less common than with GH itself because the axis self-limits.

• Active malignancy.
• Known hypersensitivity to sermorelin or mannitol in the original formulation.
• Untreated hypothyroidism, which blunts the GH response and should be corrected first.
• Pregnancy and breastfeeding.

• synergyipamorelin — The most commonly compounded clinic blend after CJC/Ipa.
• conflictsomatropin — Exogenous GH suppresses the pituitary response; sermorelin is a step-down option, not a co-therapy.
• conflictGlucocorticoids — Supraphysiological steroids directly suppress the GH response to GHRH.
• cautionLevothyroxine — Untreated hypothyroidism blunts the response; correcting thyroid status can change the effective dose.

• · IGF-1 at baseline, eight weeks and then quarterly.
• · Thyroid function, since hypothyroidism blunts the GH axis and GH therapy can unmask it.
• · Fasting glucose and HbA1c annually on long-term use.

Formerly FDA-approved as Geref and withdrawn in 2008; currently available in the US only through compounding pharmacies, and it remains on the FDA's category 1 bulk-substances list unlike most peptides in this class. Prohibited in sport under WADA S2.

• Geref (sermorelin acetate) FDA prescribing information, discontinued 2008 (label)
• Clinical use of GHRH(1-29) for diagnosis of GH deficiency and paediatric growth failure (review)

Sermorelin is residues 1 to 29 of native human GHRH, verified here directly against UniProt P01286, amidated at the C-terminus. It is the shortest fragment retaining full biological activity, which tells you something structurally: the receptor-binding and activation determinants all sit in the N-terminal third, and residues 30 to 44 contribute stability and not much else. Signalling is textbook Gs: adenylate cyclase, cAMP, PKA, CREB, driving both GH release and GH1 transcription, plus somatotroph proliferation over longer timeframes. The clinically important consequence of working here rather than at the GH receptor is that two intact feedback systems remain in place. IGF-1 rising from the liver feeds back on the pituitary and hypothalamus to suppress further GH release, and GH itself stimulates hypothalamic somatostatin. Between them, they impose a ceiling. This is why sermorelin does not produce acromegaly and why the dose-response flattens above about 1 mg, and it is the honest pharmacological basis for the claim that secretagogues are safer than exogenous GH - not marketing, but a real structural difference. The diagnostic use follows from the same logic: if the somatotroph is intact, GHRH provokes a response; if it is not, nothing happens. That is why Geref was approved both as a therapy and as a pituitary-function test. The drawback is equally structural. DPP-4 destroys it in minutes, so a single injection delivers one short square wave of cAMP signalling, and if somatostatin tone happens to be high at that moment you get very little. Everything else in this class is an attempt to fix that.

The commonest disappointment is expecting somatropin results from a physiological stimulus. Sermorelin cannot overdrive the axis - that is the whole design - so someone comparing notes with a friend on 4 IU of GH is comparing two different categories of intervention. The second problem is the beyond-use date. Compounding pharmacies assign 28 days for a reason; sermorelin degrades in solution faster than the modified analogues, and stretching a 9 mg vial to eight weeks means the last fortnight is close to placebo. The third is the fed state, same as the rest of the class. The fourth is more subtle and worth knowing: because clinic protocols often run five nights on and two off, and because the response is genuinely modest, people sometimes conclude at week four that nothing is happening and quit before the eight-week IGF-1 draw that would have told them. Finally, sermorelin's marketing has drifted a long way from its evidence. It was approved for paediatric growth failure and as a diagnostic test for pituitary reserve; the adult anti-aging indication that virtually every clinic sells has never been through a registration trial, and the gap between those two facts is the thing to hold in mind.

1. 200 mcgWeeks 1 to 2 — 200 mcg nightly, at least two hours after the last meal. Two weeks at this dose establishes tolerability - injection-site reactions were the most common adverse event in the original trials and they usually settle.
2. 300 mcgWeeks 3 to 8 — 300 mcg nightly, the most common clinic maintenance dose. Hold here through week 8 and draw IGF-1 before changing anything.
3. 500 mcgWeek 9 onward, only if IGF-1 has not moved — 500 mcg nightly. Only step here after confirming thyroid status is normal, food timing is right and the vial is within its beyond-use date. Recheck IGF-1 at week 16.
4. 1 mgCeiling — 1 mg nightly is the practical top of the range. Above this the dose-response is flat and cost rises faster than effect. If 1 mg does not move IGF-1, the problem is not the dose - it is either the pituitary, the thyroid, the product or the protocol.

• GHRH receptor (GHRHR), pituitary somatotroph — Native ligand affinity - this is the endogenous agonist fragment, so by definition it is the reference point rather than an analogue with a comparison

  Gs coupling, cAMP, PKA, CREB. GH release plus GH1 transcription plus somatotroph trophic support.

• Hypothalamic and pituitary feedback loops (intact) — Not applicable

  IGF-1 negative feedback and GH-stimulated somatostatin release both remain operative, capping the achievable GH elevation. This is the mechanistic reason sermorelin cannot produce acromegalic changes.

• Dipeptidyl peptidase-4 (substrate, not target) — Cleaves Tyr1-Ala2 rapidly

  Inactivation to GHRH(3-29) within minutes. The defining pharmacokinetic limitation of the molecule.

GH rises within ten minutes and peaks at 15 to 30 minutes, back to baseline within about an hour. Injection-site redness, if it happens, is immediate. A transient metallic taste is described in the original label and passes in minutes. Sleep changes are the first subjective effect, typically in the first one to two weeks. IGF-1 is worth measuring at week 8 and not before. Body composition changes on sermorelin are slow and modest - three to six months is the honest timeframe, and the effect size is small compared with exogenous GH. Nothing accumulates and nothing needs washing out; a single missed night has no carryover consequence.

Sermorelin plus ipamorelin is the second most commonly compounded blend after CJC/Ipa, and the pharmacology is the same argument: GHRH sets amplitude, GHRP removes the somatostatin brake. Because sermorelin's half-life is even shorter than Mod GRF's, timing precision matters more, not less - both drawn into one syringe, one injection, bedtime, fasted. The interactions that actually change outcomes are the suppressive ones. Supraphysiological glucocorticoids directly blunt the somatotroph response to GHRH; if someone is on prednisone, sermorelin will underperform and no dose increase fixes that. Untreated hypothyroidism does the same thing and is far more common than people expect. Oral oestrogen substantially reduces the IGF-1 response to any GH-axis stimulus by a first-pass hepatic effect, and transdermal does not - a woman on oral oestradiol may need a meaningfully higher dose or, better, a route change. Exogenous somatropin is a conflict, not a stack: sermorelin is the step-down option after GH, not a companion to it.

Against Mod GRF 1-29: same receptor, same pulse, roughly a third of the half-life, and a completely different supply chain. The tetrasubstituted fragment is cheaper and marginally longer-acting; sermorelin is legitimately obtainable, quality-controlled and has an actual regulatory history. For most people the deciding factor is access, not pharmacology. Against tesamorelin: tesamorelin is the same receptor family with a documented visceral-fat effect, an FDA approval and dosing an order of magnitude higher; it is what you use if you want a specific measurable outcome rather than general GH-axis support. Against CJC-1295 with DAC: the DAC version produces far larger and more sustained IGF-1 elevation, with proportionally more water retention, joint aching and glucose drift; sermorelin is the conservative end of the same receptor. Against somatropin: not comparable in magnitude, and that is the point - sermorelin's feedback loops are intact, which caps both the benefit and the harm. Against a GHRP alone: sermorelin alone underperforms almost any GHRP alone on acute GH release, which is why the blends exist.

$100–$350/month. Compounded pharmacy pricing in the US, typically 150 to 300 USD a month for a 9 or 15 mg vial through a telehealth or anti-aging clinic, before the consultation fee that usually accompanies it. Blended sermorelin-ipamorelin vials sit at the upper end. This is genuinely more expensive than the grey-market GHRH fragments, and what you are buying for the difference is sterility, identity and potency assurance. Prices are approximate and vary widely by pharmacy.

• ?No absolute subcutaneous bioavailability, volume of distribution or clearance value for sermorelin was resolved from a primary source in this session.
• ?The Geref prescribing information was not retrieved directly - it has been off the US market since 2008 and is no longer in DailyMed. Label-derived statements about adverse events and formulation are therefore secondhand and are not cited as verified.
• ?There are no controlled trials of sermorelin for the adult anti-aging, body-composition or sleep indications that make up essentially all of its current use.
• ?The five-nights-on, two-nights-off clinic convention has no published rationale or supporting data that this session could locate.
• ?Whether sermorelin plus ipamorelin outperforms sermorelin alone in humans over weeks, as opposed to on an acute GH curve, has not been tested.
• ?Sermorelin's continued presence on the FDA's category 1 bulk drug substances list, referenced in the Core record, was not independently reverified in this session.

• Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men Soule S, King JA, Millar RP, Journal of Clinical Endocrinology and Metabolism, 1994 · PMID 7962295

  Quantifies the pharmacokinetic limitation of unmodified GHRH(1-29)NH2 in humans - the short half-life and high metabolic clearance that define sermorelin's clinical behaviour.

• Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML, Journal of Clinical Endocrinology and Metabolism, 2011 · PMID 21602453

  The reference framework for what GH-axis treatment and IGF-1 targeting actually look like in adults, and the standard against which the anti-aging clinic use of sermorelin should be judged.

• UniProtKB P01286, somatoliberin (human growth hormone-releasing hormone precursor) UniProt Knowledgebase

  Primary sequence source. Confirms sermorelin's sequence as residues 1 to 29 of mature human GHRH.

• Sermorelin, PubChem compound record CID 16132413 PubChem

  Confirms molecular formula C149H246N44O42S and molecular weight 3357.9, matching the Core record.